Página inicialGruposDiscussãoMaisZeitgeist
Pesquise No Site
Este site usa cookies para fornecer nossos serviços, melhorar o desempenho, para análises e (se não estiver conectado) para publicidade. Ao usar o LibraryThing, você reconhece que leu e entendeu nossos Termos de Serviço e Política de Privacidade . Seu uso do site e dos serviços está sujeito a essas políticas e termos.

Resultados do Google Livros

Clique em uma foto para ir ao Google Livros

Carregando...

Innovation and technology adoption in health care markets

de Anupam B. Jena

MembrosResenhasPopularidadeAvaliação médiaConversas
3Nenhum(a)4,218,785Nenhum(a)Nenhum(a)
The twentieth century brought tremendous advances in health care technology, from antibiotics to laparoscopic surgery to targeted therapies for cancer--but these gains have been expensive. Governments are struggling to control burgeoning expenditures without compromising the quality of health care. Increasingly, these efforts have relied on "cost-effectiveness analysis" that balances costs against patient benefits to determine which treatments will qualify for reimbursement. Is the use of cost-effectiveness analysis to guide technology adoption wise? Although reimbursement criteria may satisfy government health budgets today, they threaten to stifle the innovation that will generate new breakthroughs in health care technologies tomorrow. Such criteria benefit current patients by lowering the cost of health care in the short term, but they also hurt future patients by limiting producers' incentives for further medical innovation. Developers of drugs to treat HIV/AIDS, for example, earn lifetime profits equal to only 5 percent of the estimated $1.4 trillion social value of their treatments. How can policymakers reward innovators adequately--and thereby secure the welfare of future patients--while ensuring that current patients have access to much-needed new treatments? In this book, Anupam B. Jena and Tomas J. Philipson argue that further use of cost-effectiveness analysis to curb health care spending may do more harm than good. Governments should adopt a more inclusive view of cost-effectiveness, one that reflects not only the short-term costs to patients but also the long-term effect on medical innovation. Policymakers should provide sufficient incentives for companies to develop new health care technologies--or risk a dangerous shortage of life-saving drugs in the future.… (mais)
Adicionado recentemente porzhuazhua88, StevensHenagerIdaho
Nenhum(a)
Carregando...

Registre-se no LibraryThing tpara descobrir se gostará deste livro.

Ainda não há conversas na Discussão sobre este livro.

Sem resenhas
sem resenhas | adicionar uma resenha
Você deve entrar para editar os dados de Conhecimento Comum.
Para mais ajuda veja a página de ajuda do Conhecimento Compartilhado.
Título canônico
Título original
Títulos alternativos
Data da publicação original
Pessoas/Personagens
Lugares importantes
Eventos importantes
Filmes relacionados
Epígrafe
Dedicatória
Primeiras palavras
Citações
Últimas palavras
Aviso de desambiguação
Editores da Publicação
Autores Resenhistas (normalmente na contracapa do livro)
Idioma original
CDD/MDS canônico
LCC Canônico

Referências a esta obra em recursos externos.

Wikipédia em inglês

Nenhum(a)

The twentieth century brought tremendous advances in health care technology, from antibiotics to laparoscopic surgery to targeted therapies for cancer--but these gains have been expensive. Governments are struggling to control burgeoning expenditures without compromising the quality of health care. Increasingly, these efforts have relied on "cost-effectiveness analysis" that balances costs against patient benefits to determine which treatments will qualify for reimbursement. Is the use of cost-effectiveness analysis to guide technology adoption wise? Although reimbursement criteria may satisfy government health budgets today, they threaten to stifle the innovation that will generate new breakthroughs in health care technologies tomorrow. Such criteria benefit current patients by lowering the cost of health care in the short term, but they also hurt future patients by limiting producers' incentives for further medical innovation. Developers of drugs to treat HIV/AIDS, for example, earn lifetime profits equal to only 5 percent of the estimated $1.4 trillion social value of their treatments. How can policymakers reward innovators adequately--and thereby secure the welfare of future patients--while ensuring that current patients have access to much-needed new treatments? In this book, Anupam B. Jena and Tomas J. Philipson argue that further use of cost-effectiveness analysis to curb health care spending may do more harm than good. Governments should adopt a more inclusive view of cost-effectiveness, one that reflects not only the short-term costs to patients but also the long-term effect on medical innovation. Policymakers should provide sufficient incentives for companies to develop new health care technologies--or risk a dangerous shortage of life-saving drugs in the future.

Não foram encontradas descrições de bibliotecas.

Descrição do livro
Resumo em haiku

Current Discussions

Nenhum(a)

Capas populares

Links rápidos

Avaliação

Média: Sem avaliação.

É você?

Torne-se um autor do LibraryThing.

 

Sobre | Contato | LibraryThing.com | Privacidade/Termos | Ajuda/Perguntas Frequentes | Blog | Loja | APIs | TinyCat | Bibliotecas Históricas | Os primeiros revisores | Conhecimento Comum | 207,257,636 livros! | Barra superior: Sempre visível